First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer.

Journal:

Journal of Clinical Oncology

Published:

2026-04-21

DOI:

10.1200/jco-25-02016

Affiliations:

21

Authors:

21

Go to article

Institutions	Authors	Share
Pfizer, United States of America (USA)	5.000000	0.24
Beth Israel Deaconess Medical Center (BIDMC), United States of America (USA)	1.000000	0.05
Comprehensive Cancer Centers of Nevada (CCCN), United States of America (USA)	1.000000	0.05
Sarah Cannon Research Institute - UK, United Kingdom (UK)	1.000000	0.05
HM Hospitales, Spain	1.000000	0.05
UH Seidman Cancer Center, CWRU, United States of America (USA)	1.000000	0.05
Vall d'Hebron University Hospital (HUVH), ICS, Spain	1.000000	0.05
University Hospital of Lausanne (CHUV), UNIL, Switzerland	1.000000	0.05
Providence Cancer Institute of Oregon, United States of America (USA)	1.000000	0.05
Institute Gustave-Roussy (IGR), France	1.000000	0.05
Instituto de Investigación Marqués de Valdecilla (IDIVAL), HUMV, Spain	1.000000	0.05
START Madrid-CIOCC, Spain	1.000000	0.05
The University of Texas MD Anderson Cancer Center, United States of America (USA)	1.000000	0.05
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	1.000000	0.05
South Texas Accelerated Research Therapeutics, LLC (START), United States of America (USA)	1.000000	0.05
Sarah Cannon Research Institute (SCRI), United States of America (USA)	0.500000	0.02
Florida Cancer Specialists and Research Institute (FCS), United States of America (USA)	0.500000	0.02
The Royal Marsden NHS Foundation Trust, United Kingdom (UK)	0.500000	0.02
The Institute of Cancer Research (ICR), United Kingdom (UK)	0.500000	0.02

Interested in Oncology and Carcinogenesis?